-
Featured
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
When nonmuscle invasive bladder cancer develops after trimodality therapy for muscle invasive bladder cancer, salvage radical cystectomy isn't necessarily required, researchers have found.
-
Featured
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates
Physicians at Massachusetts General Hospital are in the early stages of testing a novel regimen for patients with muscle-invasive urothelial bladder cancer who are medically unfit for radical cystectomy or platinum-based radiosensitizing chemotherapy.
-
Featured
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
Orthotopic neobladder reconstruction is becoming the diversion procedure of choice for female cystectomy patients due to recent advances in care for female urology patients.
-
10-Year Data: Delayed BPH Surgery Linked to Increased Risk of Treatment Failure
Daniel M. Frendl, MD, PhD, Michelle M. Kim, MD, PhD, and colleagues found in men with benign prostatic hyperplasia (BPH) that long-term surgical outcomes were adversely affected by preoperative urinary retention and delays to surgery.
-
New Research Supports Trimodality Therapy for Bladder Cancer
A new Massachusetts General Hospital study compares bladder cancer treatment options and strongly supports bladder preservation with trimodality therapy.
-
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation
Using a digital immunofluorescence assay, Jason A. Efstathiou, MD, DPhil, and colleagues showed the DNA repair protein MRE11 could guide the selection of candidates for bladder-sparing trimodality therapy for muscle-invasive bladder cancer, as higher levels were associated with 58% better cumulative four-year survival.
Bladder Contributors
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Massachusetts General Hospital, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic, Massachusetts General Hospital
Recent Article
New Research Supports Trimodality Therapy for Bladder Cancer -
Marc Dror Michaelson, MD, PhD
Clinical Director, Genitourinary Cancer Center
Recent Article
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates -
Matthew F. Wszolek, MD
Chair of Quality and Safety, Department of Urology, Massachusetts General Hospital, Urological Oncologist, Mass General Cancer Center, Instructor in Surgery, Harvard Medical School
Recent Article
Mortality Related to Surgical Staplers and Clip Appliers Is Increasing
-
Michael L. Blute, MD
Chief, Department of Urology, Walter S. Kerr, Jr., Professor of Surgery, Harvard Medical School
Recent Article
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Alternative Chemoradiation Regimen of Trimodal Therapy Found Effective for Muscle-invasive Bladder Cancer
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.